Investor Information

The Infrastructure
Layer for Psychiatry

CALI is building the first psychiatric-grade continuous monitoring platform — starting with bipolar disorder, the highest-acuity, most underserved diagnostic gap in mental health.

Market Opportunity

A massive underserved market at the intersection of psychiatric care and digital health.

0M+
Bipolar Disorder Prevalence
people globally living with bipolar disorder
$0.0B
US Digital Mental Health Market
US digital mental health market
0-year
Average Diagnostic Delay
average delay between bipolar onset and diagnosis
$0.0B
Addressable Market
serviceable addressable market for CALI

Technology Differentiation

Four structural advantages that create durable defensibility.

5-Sensor Psychiatric-Specific Design

Unlike general wellness wearables, NeuroPatch integrates EDA, EMG, temperature, accelerometry, and cortisol in a single patch. This sensor profile was explicitly selected for bipolar disorder monitoring based on peer-reviewed physiological evidence.

On-Device BiLSTM Inference

The BiLSTM model runs on-device, enabling real-time prodromal detection without cloud round-trips. Patient data is processed locally, minimizing PHI exposure and reducing latency.

HIPAA-First Architecture

Privacy and security are architectural constraints, not afterthoughts. On-device preprocessing, encrypted BLE streaming, role-based access control, and PHI decoupling are built into every layer.

24-27% CAGR Market

The digital mental health monitoring market is projected to grow at 24–27% CAGR through 2029, driven by clinician demand for objective biomarkers and payer interest in reducing inpatient costs.

Leadership

MJ

Madhura Abhijit Joshi

Founder & CEO

Leading CALI's mission to bring continuous physiological monitoring to psychiatric care. Driving product development, clinical strategy, and regulatory pathway for NeuroPatch.

Development Timeline

Clear milestones from prototype to commercial launch.

Completed
Prototype
2023
  • Hardware prototype built
  • 5-channel signal validated
  • BiLSTM architecture defined
In Progress
Pilot Study
2024-2025
  • Sensor validation in progress
  • BiLSTM model development in progress
  • Feasibility study protocol in development
Upcoming
Multi-Center Trial
2025-2026
  • Multi-site study across two institutions
  • IRB protocol submission
  • Data collection and analysis
Upcoming
FDA Submission
2026-2027
  • Type II medical device classification
  • Clinical data compilation
  • Regulatory counsel engaged
Upcoming
Commercial Launch
2027
  • Initial clinical partnerships
  • Reimbursement pathway
  • Scale manufacturing

Request Investor Packet

Get access to our full investor deck, technical documentation, and current funding terms. Contact Madhura directly or submit via our contact form.